日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

(131)I-间碘苄胍联合Dinutuximab±Vorinostat治疗复发或难治性神经母细胞瘤患者的I期研究:神经母细胞瘤治疗新方法试验

Cash Thomas, Marachelian Araz, DuBois Steven G, Chi Yueh-Yun, Baregamyan Anahit, Groshen Susan G, Jonus Hunter C, Shamirian Anasheh, Crowley Mary, Goodarzian Fariba, Acharya Patricia T, Pawel Bruce, Erbe Amy K, Shahi Ankita, Zaborek Jen, Kennedy Eleanor, Asgharzadeh Shahab, Villablanca Judith G, Pinto Navin, Weiss Brian D, Mosse Yael P, Desai Ami V, Macy Margaret E, Granger Meaghan, Vo Kieuhoa T, Sondel Paul M, Matthay Katherine K, Park Julie R, Goldsmith Kelly C

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

一项针对复发性神经母细胞瘤患者的高剂量DFMO、塞来昔布、环磷酰胺和拓扑替康联合治疗的I期研究:一项神经母细胞瘤治疗新方法试验

Hogarty, Michael D; Ziegler, David S; Franson, Andrea; Chi, Yueh-Yun; Tsao-Wei, Denice; Liu, Kangning; Vemu, Rohan; Gerner, Eugene W; Bruckheimer, Elizabeth; Shamirian, Anasheh; Hasenauer, Beth; Balis, Frank M; Groshen, Susan; Norris, Murray D; Haber, Michelle; Park, Julie R; Matthay, Katherine K; Marachelian, Araz

Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer

确保非肌层浸润性膀胱癌膀胱保留临床试验中生物标志物研究的成功

McConkey, David J; Baumann, Brian C; Cooper Greenberg, Stephanie; DeGraff, David J; Delacroix, Scott E; Efstathiou, Jason A; Foster, Jared; Groshen, Susan; Kadel, Edward E; Khani, Francesca; Kim, William Y; Lerner, Seth P; Levin, Trevor; Liao, Joseph C; Milowsky, Matthew I; Meeks, Joshua J; Miyamoto, David T; Mouw, Kent W; Pietzak, Eugene J; Solit, David B; Sundi, Debasish; Tawab-Amiri, Abdul; West, Pamela J; Wobker, Sara E; Wyatt, Alexander W; Apolo, Andrea B; Black, Peter C

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

劳拉替尼联合或不联合化疗治疗ALK驱动的难治性/复发性神经母细胞瘤:1期临床试验结果

Goldsmith, Kelly C; Park, Julie R; Kayser, Kimberly; Malvar, Jemily; Chi, Yueh-Yun; Groshen, Susan G; Villablanca, Judith G; Krytska, Kateryna; Lai, Lillian M; Acharya, Patricia T; Goodarzian, Fariba; Pawel, Bruce; Shimada, Hiroyuki; Ghazarian, Susan; States, Lisa; Marshall, Lynley; Chesler, Louis; Granger, Meaghan; Desai, Ami V; Mody, Rajen; Morgenstern, Daniel A; Shusterman, Suzanne; Macy, Margaret E; Pinto, Navin; Schleiermacher, Gudrun; Vo, Kieuhoa; Thurm, Holger C; Chen, Joseph; Liyanage, Marlon; Peltz, Gerson; Matthay, Katherine K; Berko, Esther R; Maris, John M; Marachelian, Araz; Mossé, Yael P

Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials

伦理与临床研究:提高I期肿瘤临床试验的透明度和知情同意率

Frankel, Paul H; Groshen, Susan; Beumer, Jan H; Cleveland, Laura; Kim, Edward S; Karp, Judith E

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

一项针对复发或难治性神经母细胞瘤患者的随机II期试验:MIBG对比MIBG、长春新碱和伊立替康对比MIBG和伏立诺他:来自NANT联盟的报告

DuBois, Steven G; Granger, M Meaghan; Groshen, Susan; Tsao-Wei, Denice; Ji, Lingyun; Shamirian, Anasheh; Czarnecki, Scarlett; Goodarzian, Fariba; Berkovich, Rachel; Shimada, Hiroyuki; Villablanca, Judith G; Vo, Kieuhoa T; Pinto, Navin; Mosse, Yael P; Maris, John M; Shusterman, Suzanne; Cohn, Susan L; Goldsmith, Kelly C; Weiss, Brian; Yanik, Gregory A; Twist, Clare J; Irwin, Meredith S; Haas-Kogan, Daphne A; Park, Julie R; Marachelian, Araz; Matthay, Katherine K

Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study

膀胱保留术后男性与女性肿瘤治疗结果的差异:一项基于人群的队列研究

Ballas, Leslie K; Navarro, Stephanie; Luo, Chunqiao; Fossum, Croix C; Farias, Albert; Daneshmand, Siamak; Groshen, Susan

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879

组蛋白去乙酰化酶抑制剂伏立诺他(辛酰苯胺异羟肟酸;SAHA)治疗复发性或转移性尿路上皮移行细胞癌的II期研究——一项由美国国家癌症研究所-癌症治疗扩展计划(NCI-CTEP)资助的加州癌症联盟试验,NCI 6879

Quinn, David I; Tsao-Wei, Denice D; Twardowski, Przemyslaw; Aparicio, Ana M; Frankel, Paul; Chatta, Gurkamal; Wright, John J; Groshen, Susan G; Khoo, Stella; Lenz, Heinz-Josef; Lara, Primo N; Gandara, David R; Newman, Edward

Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project

pT3期膀胱癌的预后标志物:来自国际膀胱癌组织芯片项目的研究

Wang, Gang; Black, Peter C; Goebell, Peter J; Ji, Lingyun; Cordon-Cardo, Carlos; Schmitz-Dräger, Bernd; Hawes, Debra; Czerniak, Bogdan; Minner, Sarah; Sauter, Guido; Waldman, Frederic; Groshen, Susan; Cote, Richard J; Dinney, Colin P

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

一项针对恶性实体瘤患者的静脉注射芬瑞替尼(4-HPR)的I期研究

Thomas, Jacob S; El-Khoueiry, Anthony B; Maurer, Barry J; Groshen, Susan; Pinski, Jacek K; Cobos, Everardo; Gandara, David R; Lenz, Heinz J; Kang, Min H; Reynolds, C Patrick; Newman, Edward M